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Abstract. Diabetic cardiomyopathy is characterized by structural and 
functional alterations in the heart muscle of people with diabetes that 
finally lead to heart failure. Metabolic disturbances characterized by 
increased lipid oxidation, intramyocardial triglyceride accumulation 
and reduced glucose utilization have all been involved in the 
pathogenesis of diabetic cardiomyopathy. On the other hand, 
evidences arisen in the recent years point to a potential link between 
chronic low-grade inflammation in the heart and metabolic 
dysregulation. Interestingly, the progression of heart failure and 
cardiac hypertrophy usually entails the activation of pro-inflammatory 
pathways. Therefore, in this chapter we summarize novel insights into 
the crosstalk between inflammatory processes and metabolic 




 The human heart produces, and immediately hydrolyzes, approx. 30 kg of 
ATP every day to carry out the mighty job of pumping more than 7,000  L/day                 
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of blood. Therefore, it is not surprising that any abnormality that deregulates 
its proper working may become life-threatening. In fact, heart disease is the 
major cause of death for both men and women in developed countries and, 
according to the World Health Organization, by 2020 it is expected to be the 
leading cause of death throughout the world. Heart disease is often grouped 
with metabolic disorders because it is frequently a consequence of 
uncorrected type 2 diabetes and obesity-related dyslipidemia. Insulin 
resistance, which is a hallmark of type 2 diabetes, is a risk factor of heart 
failure, the leading cause of death in type 2 diabetic patients. Diabetic 
cardiomyopathy, which refers to structural and functional alterations in the 
heart muscle of people with diabetes that finally lead to heart failure, is 
related to disturbances in myocardial energy metabolism. Diabetic 
cardiomyopathy is only said to exist if heart failure is not accompanied by 
coronary artery disease or hypertension that may account for the heart 
muscle disorder. 
 An increasing body of evidence suggests a potential link between 
chronic low-grade inflammation and metabolic disorders that are associated 
with abnormal cytokine production and increased levels of saturated fatty 
acids, such as insulin resistance, type 2 diabetes and obesity. The 
progression of heart disease usually entails a local rise in pro-inflammatory 
cytokines, including interleukin (IL)-6, monocyte chemoattractant protein-1 
(MCP-1) and tumour necrosis factor-α (TNF-α) [1]. These molecules exert 
several autocrine and paracrine effects in cardiac cells via downstream 
activation of the transcription factor nuclear factor (NF)-κB, which may 
contribute to states that are associated with myocardial inflammation, for 
example heart failure and dilated cardiomyopathy. However, the underlying 
mechanisms linking inflammation, heart failure and dilated cardiomyopathy 
are complex, since they are coupled to systemic metabolic abnormalities and 
changes in cardiomyocyte phenotype. In this review we summarize recent 
insights into the crosstalk between inflammatory processes and metabolic 
dysregulation in the failing heart during diabetes. 
 
1. Metabolic regulation in the healthy heart 
 
 Free fatty acids are the preferred energy substrate in the adult heart, 
supplying about 70% of total ATP [2]. However, since the human heart 
requires a constant supply of fuel, other substrates such as glucose (20%) 
or lactate (10%) may provide additional fuel sources in diverse 
physiological and nutritional circumstances. Glucose uptake is mostly 
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regulated by glucose transporters (GLUTs), of which GLUT4 is the most 
abundant in cardiac cells (Fig. 1) [3]. Once inside the cytosol, glucose is 
phosphorylated into glucose-6-phosphate, which can either be stored as 
glycogen or converted into pyruvate, the end product of glycolysis. Then, 
pyruvate enters the mitochondria where it undergoes oxidative 
decarboxylation by the pyruvate-dehydrogenase complex (PDC), which 
catalyses the rate-limiting step of glucose oxidation. Specific PDC kinases 
(PDKs) are responsible for the phosphorylation-induced inactivation of 
PDC. As such, PDK4, the most expressed PDK isoform in the heart, 
decreases glucose oxidation while allowing increased fatty acid -oxidation. 
With regard to the fatty acids, they cross the cardiomyocyte cell membrane 
through passive diffusion or by specific transport proteins, including fatty 
acid translocase (FAT/CD36), fatty acid binding protein (FABP) and fatty 
acid transport protein 1 (FATP1). In the cytoplasm, fatty acids are 
acylated, and either enter the mitochondria by the action of carnitine 
palmitoyl transferase 1 (CPT-1) or are incorporated into the intracellular 
lipid pool in the form of triglycerides. In the mitochondrial matrix, fatty 
acids are oxidized by the β-oxidation pathway to form acetyl-CoA. At this 
point, pathways for glucose and fatty acid oxidation merge, since acetyl-
CoA, which is produced from both pathways, enters the tricarboxylic acid 
(TCA) cycle. Finally, reduced flavin adenine dinucleotide (FADH2) and 
nicotinamide adenine dinucleotide (NADH) generated through β-oxidation 
and the TCA cycle, respectively, carry electrons to the electron transport 
chain, thus driving ATP synthesis by oxidative phosphorylation. 
 Under physiological conditions, glucose utilization is reduced in the 
heart by increased fatty acid oxidation via the Randle cycle. After a high 
carbohydrate supply, insulin activates the protein kinase B (PKB)/Akt 
signalling pathway and subsequent translocation of GLUT4 from 
intracellular vesicles towards the sarcolemma, the cell membrane of 
cardiac cells. As such, insulin promotes glucose uptake and utilization, 
thereby reducing myocardial oxygen consumption and increasing cardiac 
efficiency [4]. Insulin also enhances the uptake of fatty acids, but instead 
of being oxidized, they are stored in the intracellular pool of lipids. The 
AMP-activated protein kinase (AMPK) is another important regulator of 
cardiac energy homeostasis. Conditions leading to energy depletion, for 
instance the failing heart or increased ATP demand, lead to AMPK 
activation, which switches off energy-consuming pathways and stimulates 
ATP-producing pathways such as fatty acid -oxidation and glycolysis. 
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Figure 1. Metabolic regulation in the normal heart. Glucose, after uptake by 
specific transporters (GLUT4), is phosphorylated and can either be stored as 
glycogen or converted into pyruvate (glycolysis). In the mitochondria, pyruvate 
undergoes oxidative decarboxylation by the pyruvate-dehydrogenase complex 
(PDC). Long-chain fatty acids (LCFA) that enter into the cytoplasm by passive 
diffusion or specific transporters (FAT/CD36) are acylated by acyl-CoA synthetase 
(ACS), and either enter the mitochondria (carnitine palmitoyl transferase 1,      
CPT-1), or are incorporated into triglycerides (TG). In the mitochondrial matrix, 
fatty acids undergo β-oxidation to form acetyl-CoA. The acetyl-CoA formed 
during glucose or fatty acid oxidation enters the tricarboxylic acid (TCA) cycle and 
finally generates ATP through oxidative phosphorylation. Initiation of the insulin 
receptor substrate 1 (IRS-1) cascade by insulin induces the phosphatidylinositol 3 
kinase (PI3K), which activates the protein kinase B (PKB)/Akt. AMPK promotes 
myocardial GLUT4 activity and stimulates glycolytic enzymes, while it induces 
CPT-1 activity through acetyl-CoA carboxylase (ACC) phosphorylation-mediated 
inhibition. 
“Reprinted from Palomer et al., International Journal of Cardiology, 168:3160-3172, 
Copyright  (2013), with permission from Elsevier Limited”.  
 
 Cardiac metabolism is mostly regulated at the transcriptional level by 
the peroxisome proliferator-activated receptor (PPAR) transcription factor 
family, which consists of three isoforms, PPAR  (or NR1C1), PPAR /  
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(NR1C2) and PPAR  (NR1C3). The PPAR family of ligand-activated 
nuclear receptors require heterodimerization with another nuclear receptor, 
the 9-cis-retinoic acid receptor (RXR or NR2B), in order to be activated. 
Heterodimerization is then followed by coactivator recruitment and 
subsequent binding to DNA specific sequences called PPAR-response 
elements (PPRE), located within the promoter regions of PPAR target 
genes. Notable among the PPAR target genes with identified PPREs are 
those coding for lipid and glucose homeostasis. PPAR  and PPAR /  are 
the predominant isoforms in the heart, where they share some overlapping 
functions [5]. Transgenic mice with constitutive overexpression of 
PPAR /  in the heart show increased myocardial glucose utilization, do 
not accumulate myocardial lipids and display normal cardiac function [6]. 
Another study has reported that constitutive cardiac overexpression of 
PPAR /  in adult mice results in elevated myocardial oxidative 
metabolism, while myocardial glycogen content and the activity of the 
PDC and AMPK are markedly reduced, overall resulting in improved 
cardiac function [7]. In agreement with this, cardiomyocyte-restricted 
PPAR /  deficiency in mice leads to cardiac pathological development 
[8]. The best-characterized coactivator of PPARs is the cardiac-enriched 
PPAR  coactivator-1 (PGC-1) , which regulates the expression of several 
genes involved in the electron transport chain, mitochondrial biogenesis, 
fatty acid -oxidation and glucose oxidative metabolism, including PDK4. 
PDK4 gene expression is known to be controlled by a plethora of different 
transcription factors. Some of them are coactivated by PGC-1 : PPARs, 
oestrogen-related receptors (ERRs) and the forkhead transcription factor 
(FOXO1 or FKHR); but others acting in a PGC-1 -independent manner: 
E2F1, LXR (liver X receptor) or RXR (retinoid X receptor). 
 
2. Metabolic remodelling in the development of diabetic 
cardiomyopathy 
 
 The heart has the capacity to adapt to various pathophysiological 
conditions by adjusting its relative metabolism of carbohydrates and fatty 
acids. The loss of this metabolic flexibility is associated with pathological 
cardiac hypertrophy and heart failure. During diabetes, the occurrence of 
insulin resistance in the myocardium, together with increased rates of 
systemic lipolysis, means that the heart relies almost exclusively on 
mitochondrial fatty acid -oxidation as the sole fuel source [6]. Reduced 
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myocardial glucose uptake and utilization owing to altered insulin 
signalling may account for the loss of this capacity to switch between 
glucose and fatty acids in insulin-resistant and insulin-deficient forms of 
diabetes. Despite the higher fatty oxidation rate that occurs in the diabetic 
heart, myocardial lipid accumulation is a feature of this disease. The heart 
is not a major site of lipid storage, but fatty acids can be stored as 
triacylglycerols and phospholipids within the cardiomyocyte, particularly 
when they are abundant, as occurs with diabetes or obesity. If this 
accumulation persists over time, the heart will begin to accumulate toxic 
lipid intermediates linked to the development of insulin resistance and 
lipotoxic cardiomyopathy. In fact, there is a strong correlation between 
intracardiac lipid accumulation and heart failure in humans [9]. 
 Metabolic dysregulation occurring in the heart of obese and diabetic 
patients often involves derangements in the activity of both PPARs and 
PGC-1 . The expression and activity of PPAR  and PGC-1  are increased 
in the early stages of insulin resistance in the heart [10], thus promoting 
excessive utilization of fatty acids instead of glucose, and driving diabetic 
cardiomyopathy [6]. In contrast, in overt diabetes the expression and activity 
of PPAR  and PGC-1  are reduced, inducing mitochondrial dysfunction 
and cardiac hypertrophy [11]. Some debate exists about the role of PGC-1  
during diabetes, since it has been reported to be down-regulated in the 
myocardial tissue of streptozotocin-induced diabetic rats, a fact which is 
accompanied by a reduction in left ventricular function [12], but also 
activated in streptozotocin-induced mice [13]. PPAR /  also plays an 
important role in diabetic cardiomyopathy. It has been demonstrated that 
deletion of the PPAR /  gene in the heart results in cardiac dysfunction, 
cardiac hypertrophy and myocardial lipid accumulation [14]. Diabetic 
cardiomyopathy induced with streptozotocin in rats is associated with 
ventricular hypertrophy, intramyocardial lipid accumulation and a marked 
decrease in cardiac PPAR /  protein levels [15]. Furthermore, PPAR /  
protein levels are reduced in neonatal rat cardiomyocytes and rat H9c2 
cardiomyoblasts exposed to hyperglycaemia [15].  
 Transgenic mice with cardiac-specific overexpression of PDK4, and 
thus with chronic suppression of glucose oxidation, exhibit an insulin-
resistant profile characterized by low glucose oxidation rates and high fatty 
acid catabolism [16]. This shift in the substrate preference constrains 
metabolic flexibility and predisposes to cardiomyocyte fibrosis and 
cardiomyopathy. Interestingly, transgenic PDK4 mice are protected against 
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high-fat diet-induced myocyte lipid accumulation, probably owing to their 
increased capacity for mitochondrial fatty acid oxidation. This is related to 
the activation of AMPK and its known target, PGC-1 , and the increased 
capacity for uncoupled mitochondrial respiration. 
 
3. The role of NF- B-induced inflammation in diabetic 
cardiomyopathy 
 
 Under various pathological stimuli, the human myocardium secretes a 
number of pro-inflammatory cytokines and chemokines, which exert several 
pleiotropic effects in cardiac cells. Sustained increases in their levels may 
contribute to states that are associated with myocardial inflammation (i.e. 
heart failure and dilated cardiomyopathy) [17]. Pro-inflammatory cytokine 
expression is under the control of the ubiquitous and inducible transcription 
factor NF-κB, which is itself activated in congestive heart failure and cardiac 
hypertrophy [18]. Several exogenous and endogenous stimuli may induce 
NF- B transcriptional activity, notably the pro-inflammatory cytokines 
themselves, hyperglycaemia, elevated free fatty acid levels in plasma, 
reactive oxygen species, angiotensin II, endothelin 1, lipoproteins and 
anoxia. 
 In mammals, NF-κB consists of five members: p65 (RelA), RelB, c-
Rel, NF- B1 (p50 and its precursor p105) and NF- B2 (p52 and its 
precursor p100), which form either homodimers or heterodimers. The most 
abundant form of the NF- B family is the p65/p50 heterodimer, which is 
often used synonymously for NF-κB. In resting cells, NF- B is present in 
the cytoplasm as an inactive heterodimer bound to an inhibitor protein 
subunit, I B. After stimulation, the canonical or classical pathway of NF-
κB signalling involves the activation of the I B kinase (IKK) complex, 
which specifically phosphorylates I B. Phosphorylation of I B induces its 
subsequent proteasome-mediated degradation, thus releasing the NF- B 
heterodimer, which then translocates to the nucleus and binds to specific 
promoter sequences on its target genes to begin the transcription 
machinery. Furthermore, the p50/p65 heterodimer may undergo a series of 
post-translational modifications including phosphorylation, acetylation and 
methylation, which allow finely-tuned regulation of transcriptional 
activity. 
 The main cardiac responses to diabetes are oxidative stress, 
inflammation, endothelial dysfunction, cardiac fibrosis, hypertrophy and 
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apoptosis, in all of which NF- B may participate. Cardiac inflammation is 
an early and notable response to diabetes and is actively involved in the 
development of heart failure during diabetic cardiomyopathy [19]. Several 
pro-inflammatory cytokines that have elevated levels in circulation in obese 
and diabetic patients, such TNF-  and IL-6, are involved in the 
physiopathological process that relates obesity and insulin resistance in the 
heart [2]. 
   
4. Crosstalk between inflammation and metabolism in the 
diseased heart 
 
4.1. PPAR /  activation blocks lipid-induced inflammation in the heart 
 
 In the heart, excess dietary fat may result in myocardial insulin 
resistance, and is related to a range of direct effects, including 
inflammation, hypertrophy, fibrosis and contractile dysfunction. PPARs 
are capable of limiting myocardial inflammation independently of binding 
to DNA, through a mechanism termed trans-repression. Several 
mechanisms have been proposed to explain these anti-inflammatory 
effects, for example the physical interaction between PPARs and NF- B, 
thereby resulting in a functional cross-inhibition of their transcriptional 
activity. In the heart of mice fed a high-fat diet or in human cardiac AC16 
cells, treatment with the saturated fatty acid palmitate induced the 
expression of TNF- , MCP-1 and IL-6, together with the activity of NF- B 
(Fig. 2A) [20]. Interestingly, the PPAR /  agonist GW501516 abrogated 
this pro-inflammatory profile. Similarly, NF- B-dependent inflammation 
was induced in the heart of PPAR /  knockout mice, a fact which is 
consistent with the anti-inflammatory activity of PPAR /  [20]. This latter 
study reported that PPAR /  activation by GW501516 strongly enhanced 
the physical interaction between the p65 subunit of NF- B and PPAR /  
(Fig. 2B), thereby suggesting that this mechanism may also interfere with 
NF-κB trans-activation capacity in the heart. Furthermore, addition of 
GSK0660 partially blocked the enhanced interaction between p65 and 
PPAR /  in AC16 cells, thus linking this physical interaction with 
PPAR /  availability in the nucleus and its subsequent activity. Likewise, 
PPAR /  activation with its agonists L-165041 or GW0742 inhibits 
phenylephrine- and lipopolysaccharide-induced NF-κB activation in 
cultured neonatal rat cardiomyocytes and H9c2 cells through enhanced 
physical interaction between p65 and PPAR /  [21,22]. Other studies also 
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demonstrate that PPAR /  activation by ligand administration or 
adenoviral overexpression in cultured cardiac myocytes suppresses the     
NF- B signalling pathway and displays potent anti-inflammatory effects 
[13,23]. 
  















Figure 2. The PPAR /  agonist GW501516 (GW) prevents inflammation in the heart 
of mice fed a high-fat diet (HFD). (A) mRNA levels assessed by real-time RT-PCR 
(upper panel) and electrophoretic mobility shift assay showing NF- B activity (lower 
panel, Ab, antibody; NE, nuclear extract; IC, immunocomplex). *P<0.05, **P<0.01 
vs. Control; †P<0.05 vs. HFD. (B) Co-immunoprecipitation of nuclear protein extracts 
obtained from AC16 cells treated with palmitate (Pal), GW501516 (GW) and 
GSK0660 (GSK). (C) MCP-1 mRNA levels assessed by real-time RT-PCR in AC16 
cells treated with palmitate, GW501516 and compound C (Comp C). *P<0.05, 
**P<0.01 vs. Control; †P<0.05, ‡P<0.01 vs. Palmitate; &P<0.001 vs. Pal+GW. 
“Reprinted from Álvarez-Guardia et al., Biochimica et Biophysica Acta (BBA) - Molecular and 







Figure 2. The PPAR /  agonist GW501516 (GW) prevents inflammation in the 
heart of mice fed a high-fat diet (HFD). (A) mRNA levels assessed by real-time          
RT-PCR (upper panel) and electrophoretic mobility shift assay showing NF- B 
activity (l wer panel, Ab, antibody; NE, nuclear extr ct; IC, immunoc mplex). 
*P<0.05, **P<0.01 vs. Control; †P<0.05 vs. HFD. (B) Co-immunoprecipitation of 
nuclear protein extracts obtained from AC16 cells treated with palmitate (Pal), 
GW501516 (GW) and GSK0660 (GSK). (C) MCP-1 mRNA levels assessed by real-
time RT-PCR in AC16 cells treated with palmitate, GW501516 and compound C 
(Comp C). *P<0.05, **P<0.01 vs. Control; †P<0.05, ‡P<0.01 vs. Palmitate; 
&P<0.001 vs. Pal+GW. 
“Reprinted from Álvarez-Guardia et al., Biochimica et Biophysica Acta (BBA) - Molecular and 
Cell Biology of Lipids, 1811:59-67, Copyright  (2011), with permission from Elsevier 
Limited”. 
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 It has been reported that GW501516 is able to regulate lipid and 
glucose metabolism in human skeletal muscle by AMPK-dependent, but 
PPAR / -independent, mechanisms [21]. Since activation of AMPK may 
block NF- B signalling pathway through the blockade of IKK activity 
[22], it might be feasible that GW501516 was blocking lipid-induced 
inflammatory pathways in cardiac cells through AMPK-dependent 
mechanisms. An experiment in which the AMPK inhibitor compound C 
was added before GW501516 and palmitate confirmed the anti-
inflammatory role of this kinase in human cardiac AC16 cells (Fig. 2C). 
These results are relevant, especially taking into account that PPAR /  has 
been postulated as a potential target in the treatment of obesity and the 
insulin resistance state. Since chronic low-grade inflammation plays a 
significant role in cardiac hypertrophy and heart failure, and GW501516 
has been shown to ameliorate metabolic disturbances in heart caused by 
high-fat diets, it is tempting to speculate that PPAR /  might serve as a 
therapeutic target to prevent cardiac disease in metabolic disorders. 
 
4.2. The role of the PPAR/PGC-1 /PDK4 axis in the crosstalk between 
inflammatory processes and metabolism 
 
 Cardiac PGC-1  expression, along with its target transcription factors 
PPARs and ERR , are all reduced in animal models of heart failure 
[23,13] and in pathological forms of cardiac hypertrophy [24,25], 
suggesting that this decrease may be responsible for an energetic failure 
that can eventually lead to cardiac dysfunction. Likewise, PGC-1
 
knockout mice exhibit lower cardiac power and increased reliance on 
glucose oxidation [26]. Exposure of human cardiac AC16 cells to TNF-  
inhibited the expression of PGC-1 , a fact which resulted in a reduction in 
PDK4 expression and subsequent increase in the glucose oxidation rate 
(Fig. 3A) [27]. It is worth mentioning that all these changes were 
abrogated with parthenolide, thus demonstrating the involvement of the 
NF- B pathway [28]. In consonance with this, transgenic mice with 
constitutive and specific overexpression of TNF-  in the heart, a well-
characterized model of cytokine-induced cardiomyopathy, displayed 
reduced PGC-1  and PDK4 expression in the heart, and this was 
accompanied an increase in glucose utilization. In a similar way, 
phenylephrine and LPS down-regulate the expression of PGC-1  and 
PDK4 in rat neonatal cardiomyocytes, resulting in an increase in glucose 
utilization and a decrease in fatty acid oxidation, a phenotype which 
resembles that observed during cardiac hypertrophy [28,29]. Interestingly, 
Inflammation and metabolic dysregulation during diabetic cardiomyopathy 177 
the PPAR /  agonist L-165041 prevented the reduction in PDK4 
expression induced by both phenylephrine and LPS [22]. Overall data 
suggest the hypothesis that the NF- B-mediated inhibition of PGC-1  
accounts for the shift towards increased glycolysis during cardiac 
hypertrophy and heart failure. 
 An appealing question arose about the specific molecular mechanisms 
by which PGC-1  was down-regulated after NF- B activation in cardiac 
cells. Co-immunoprecipitation studies not only demonstrated that the               
p65 subunit of NF- B interacted with PGC-1  in the basal state, but also this  
 
expression and the subsequent increase in glucose oxidation observed during 





















Figure 3. The p65 subunit of NF- B binds to PGC-1  in cardiac cells. (A) PGC-
1  and PDK4 expression determined by RT-PCR and [U-14C]-glucose oxidation 





Figure 3. The p65 subunit of NF- B binds to PGC-1  in cardiac cells. (A) PGC-1  
and PDK4 expression determined by RT-PCR and [U-14C]-glucose oxidation rate in 
AC16 cells treated with TNF-  and the NF- B inhibitor parthenolide (Parth). (B) 
Co-immunoprecipitation of nuclear protein extracts obtained from AC16 cells treated 
with TNF-  and/or parthenolide. (C) Co-immunoprecipitation (left panel) of nuclear 
protein extracts obtained from AC16 cells transfected with PGC-1 , PGC-1 L2/3A 
or lacZ (Control); analysis of PDK4 gene expression determined by RT-PCR (middle 
panel, † P<0.01 vs. Control; ‡ P<0.01 vs. PGC-1 ; # P<0.01 vs. TNF- ; & P<0.001 
vs. PGC-1 +TNF- ); and [U-14C]-glucose oxidation rate expressed as a percentage 
with respect to control cells (right panel, *P < 0.05, **P < 0.01  vs. Control). 
“Reprinted from Palomer et al., Cardiovascular Research, 81:703-712, Copyright  (2009); 
and Álvarez-Guardia et al., Cardiovascular Research, 87:449-458, Copyright  (2010), with 
permission from Oxford University Press”. 
Xavier Palomer et al. 178 
binding was increased after stimulation of NF- B activity, and owing to 
p65 accumulation in the nucleus (Fig. 3B) [30]. Modulation of the PGC-1  
protein levels by means of overexpression or gene silencing demonstrated 
that the main factor limiting the degree of association between p65 and 
PGC-1  is the amount of p65 present in the nucleus. 
 PGC-1  binds nuclear receptors through three leucine-rich LXXLL 
motifs (named L1, L2 and L3), which are located within the N-terminus of 
the coactivator, and it is widely recognized that PGC-1  associates with 
other co-regulators via these LXXLL motifs [31]. Given that NF- B also 
requires the binding to specific LXXLL motifs located within the sequence 
of specific coactivators to drive gene expression [32], we investigated 
whether these motifs were responsible of the modulation of PGC-1  
activity by p65. On the basis of co-immunoprecipitation studies, and using 
a mutated form of PGC-1 , we reported that the L2 and L3 motifs play a 
crucial role in p65 binding (Fig. 3C) [30]. Therefore, in cardiac cells, the 
increased physical interaction between p65 and the L2/L3 motifs of PGC-
1  after NF- B activation might reduce PGC-1  expression, thereby 
leading to a reduction in PDK4 expression and the subsequent increase in 
glucose oxidation observed during the pro-inflammatory state (Fig. 3C) 
[30]. 
 
4.3. PPAR-independent mechanisms in the regulation of PDK4 during 
inflammation  
 
 Other mechanisms might also account for the down-regulation of 
PGC-1  after NF- B activation. For instance, NF- B activation may 
indirectly stimulate PKB/Akt [30] and, since PGC-1  contains a consensus 
binding site for PKB/Akt phosphorylation that reduces its stability, it may 
result in a diminution in its transcriptional activity [33]. PKB/Akt also has 
the capacity to phosphorylate the FOXO1 transcription factors [34], 
thereby inducing their ubiquitination-dependent degradation and 
eventually leading to a decrease in the expression of their target genes           
(i.e. PGC-1 ) [35]. 
 We have also recently proposed a novel mechanism by which the 
inflammatory processes driven by NF- B can down-regulate PDK4 through 
inhibition of the E2F1 transcription factor in a PPAR- and ERR -
independent manner. E2F1 is known for its major role in regulating the G1/S 
phase transition during cell cycle progress, hence acting as a critical 
regulator of cell survival and proliferation [36]. However, it has also been 
demonstrated that it may regulate PDK4 expression through specific sites 
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located within the promoter of the gene that encodes for the latter [37]. 
Protein co-immunoprecipitation analyses revealed that PDK4 
downregulation entailed enhanced physical interaction between the p65 
subunit of NF- B and E2F1 (Fig. 4A) [38]. The association between p65 and 
E2F1 has already been established in human [39] and murine fibroblasts 
[40]. Chromatin immunoprecipitation analyses demonstrated that p65 
translocation into the nucleus prevented the recruitment of E2F1 to the 
PDK4 promoter and its subsequent E2F1-dependent gene transcription in 
human cardiac cells (Fig. 4B), thus influencing glucose oxidation (Fig. 4C). 
Interestingly, the NF- B inhibitor parthenolide prevented the inhibition of E2F1. 
 
















Figure 4. The interplay between NF- B and E2F1 regulates metabolism in 
cardiac cells. (A) Co-immunoprecipitation of nuclear protein extracts obtained 






Figure 4. The interplay between NF- B and E2F1 regulates metabolism in cardiac 
cells. (A) Co-immunoprecipitation of nuclear protein extracts obtained from AC16 
cells treated with or without TNF-  and transfected with LacZ- or E2F1-carrying 
plasmids. (B) Chromatin immunoprecipitation demonstrating the E2F1-site fold 
enrichment at the PDK4 promoter and (C) [U-14C]-glucose oxidation rate in AC16 
cells overexpressing the human LacZ-control or the E2F1 genes incubated with TNF-
. *P<0.05, **P<0.01, ***P<0.001 vs. LacZ; †P<0.01 vs. E2F1; &P<0.01 vs. 
LacZ+TNF- . 
“Reprinted from Palomer et al., PLoS ONE, 6, e19724, Copyright  (2011), with permission 
from PLoS – Public Library of Science, and following the Creative Commons Attribution (CC 
BY) license”. 
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Based on these findings, we envision a model for the regulation of PDK4 
expression and cardiac cell metabolism by NF- B and E2F1, in which NF-
B might serve as a molecular switch that regulates E2F1-dependent 
PDK4 gene transcription. As inappropriate PDK4 activity would have 
catastrophic consequences in high-metabolic-rate organs, the basal 
repression of E2F1-dependent PDK4 expression by NF- B might be 
crucial for normal cardiac function. Since E2F1 plays an important role in 
cardiac myocyte growth and is also involved in metabolism regulation 
through PDK4 modulation, targeting this transcription factor could provide 
us with an effective therapy for treating detrimental left ventricular 
hypertrophy leading to heart failure.  
 There are several other pathways that may account for the interplay 
between inflammation and metabolic responses in the heart. For instance, 
the heart of obese mice fed a high-fat diet display a reduction in glucose 
metabolism, GLUT and AMPK activity, which is accompanied by 
macrophage infiltration and enhanced inflammation [41]. A similar profile 
is observed after IL-6 administration in mice, whereby this cytokine 
suppresses the glucose metabolism and induces insulin resistance owing to 
AMPK activity and IRS-1 inhibition [42]. In accordance with this, AMPK 
activation diminishes NF- B signalling, attenuates cardiac hypertrophy 
and improves cardiac function in rats subjected to trans-aortic constriction 
or in rat neonatal cardiomyocytes induced with angiotensin II [42]. 
 Enhanced saturated free fatty acid (e.g. palmitate) levels up-regulate 
the lipid intermediates ceramides and diacylglycerol (DAG), the latter 
being a powerful activator of protein kinase C (PKC) . Likewise, 
hyperglycaemia activates the glycolytic pathway and increases the 
production of the PKC/DAG pathway [43]. PKC activation may provoke 
insulin resistance by means of IRS-1 inhibition and inflammation through 
NF- B induction [44]. On the other hand, ceramides are lipotoxic 
molecules that modulate cellular energy metabolism and are enhanced in 
several models of lipotoxic cardiomyopathy. They are necessary and 
sufficient intermediates linking saturated fats to the inhibition of insulin 
signalling and enhanced inflammation [45]. In transgenic mice prone to 
dilated cardiomyopathy owing to ceramide accumulation in the heart, there 
is an up-regulation of fatty acid oxidation while glucose oxidation is down-
regulated [46]. This has been related to the ceramide-dependent increase in 
the expression of genes such as PDK4, and the fatty acid transporters 
FAT/CD36, FATP1 or ACS [46]. 
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 Finally, recent studies have revealed an important link between sirtuin 
1 (SIRT1), energy metabolism and inflammation [46]. The main reason for 
this link is perhaps that besides its ability to inhibit NF- B activity, SIRT1 
may associate with and deacetylate PGC-1 , leading to enhanced 
transcriptional activity of the latter. A paradigmatic example of this is 
given by the overexpression of SIRT1 in transgenic mice fed a high-fat 
diet, which show lower lipid-induced inflammation along with better 
glucose tolerance [47]. This study reported that the beneficial effects of 
SIRT1 were due both to the induction of the antioxidant proteins via 
stimulation of PGC-1 , and lower activation of pro-inflammatory 
cytokines, owing to NF- B activity down-modulation. Similarly, SIRT1 
inhibition in primary myotubes down-regulates PGC-1  and its target 
mitochondrial transcriptional regulators, ERR  and mtTFA, along with the 
expression levels of mitochondrial and fatty acid utilization genes [48]. On 
the other hand, both the activation of SIRT1 with resveratrol and 
overexpression of SIRT1 reduced phenylephrine-induced hypertrophy and 
the down-regulation of fatty acid oxidation genes in neonatal rat cardiac 
myocyte [49]. According to a study by Planavila et al. [50], SIRT1 
overexpression led to enhanced PPAR  binding to the p65 subunit of    
NF- B and subsequent p65-deacetylation, thus blocking NF- B activity. 
Consistent with this, isoproterenol-induced cardiac hypertrophy, metabolic 
dysregulation and inflammation were prevented by resveratrol in wild-type 
mice, but not in PPAR -null mice. Moreover, SIRT1 overexpression led to 
deacetylation of PGC-1  [50] and phosphorylation-induced AMPK 
activation [50]. In fact, besides the PPAR/PGC-1  pathway, SIRT1 
modulates the activity of a number of proteins involved in cardiac 
metabolic homeostasis. For instance, it has been reported an important role 
of SIRT1 in regulating the ERR transcriptional pathway during the 





 Free fatty acids are the preferred energy substrate in the adult heart, 
although other substrates such as glucose or lactate may provide additional 
fuel sources in diverse circumstances. At the transcriptional level, cardiac 
metabolism is mostly regulated by the PPAR/PGC-1 /PDK4 axis. The 
PGC-1  co-activates PPAR , PPAR /  and ERR  to regulate the 
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expression of genes involved in the electron transport chain, mitochondrial 
biogenesis, fatty acid -oxidation and glucose oxidative metabolism. One 
of its key target genes, PDK4, may promote insulin resistance through the 
inhibition of efficient glucose utilization. During diabetes, and owing to 
the insulin resistance and the dysregulation in the activity of both PPARs 
and PGC-1 , the myocardium relies almost exclusively on mitochondrial 
fatty acid -oxidation as the main fuel source. As a consequence, one of the 
hallmarks of diabetic cardiomyopathy is myocardial lipid accumulation, 
which is related to the development of lipotoxic cardiomyopathy. During 
diabetic cardiomyopathy, the excess of fatty acid oxidation in 
mitochondria induces the formation of reactive oxygen species and the 
accumulation of lipid intermediates, promoting NF- B activation and, as a 
result, contributing to cardiac inflammation and subsequent development 
of heart failure. 
 In this review, we report that PPAR activation is capable of limiting 
myocardial inflammation by means of trans-repression through several 
mechanisms, including the physical interaction between PPARs and pro-
inflammatory NF- B. Notably, PPAR  and PPAR /  activation might 
prevent metabolic disturbances occurring during diabetic cardiomyopathy, 
while inhibiting inflammatory processes in the heart. This is relevant, 
especially taking into account that PPARs have been postulated as 
potential targets in the treatment of obesity and the insulin resistance state. 
On the other hand, several studies point to PGC-1  as a potential 
contributor to cardiac dysfunction and heart failure in metabolic disorders 
with an inflammatory background. Here, we have described several well-
known and new mechanisms by which PGC-1  activity is modulated after 
NF- B induction, for instance the sequestration of PGC-1  protein by p65, 
the PKB/Akt-mediated phosphorylation of PGC-1 , or FOXO inhibition              
(Fig. 5). PGC-1  down-regulation often results in diminished PDK4 
expression, a crucial step in determining the rates of glucose and fatty acid 
oxidation in the heart. However, other mechanisms may account for PDK4 
down-regulation, including the inhibition of E2F1. 
 In summary, an increasing body of evidence suggests a potential link 
between chronic inflammation and metabolic disturbances in the heart. 
Gaining more insight into the mechanisms by which cardiac inflammatory 
processes may deregulate metabolic homeostasis in the heart may assist in 
devising new therapeutic strategies to restore cardiac function during insulin 
resistance and diabetes. 
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Figure 5. Crosstalk between inflammation and metabolism in the diseased heart. 
PPAR activation is capable of limiting myocardial NF- B activity through several 
mechanisms, such as its physical interaction with the p65 subunit of NF- B, or the 
inhibition of MAPK phosphorylation. PPAR  is also capable of inhibiting NF- B 
activity by inducing I B  expression. After NF- B activation, the increased physical 
interaction between p65 and PGC-1  reduces the transcriptional activity of the latter, 
thus diminishing its target gene expression (ACS, CPT-1, FAT/CD36, GLUT4, and 
PDK4). NF- B may also down-regulate PDK4 through inhibition of the E2F1 
transcription factor. SIRT1 down-regulates NF- B activity through p65 deacetylation 
and enhances the activities of PGC-1  and AMPK. AMPK also diminishes NF- B 
signalling due to IKK inhibition and the subsequent lowering of IkB  degradation. 
NF- B activation may also indirectly stimulate PKB/Akt, which catalyzes the 
phosphorylation-mediated inhibition of PGC-1 , and also has the capacity to 
phosphorylate FOXO1, thereby inducing its degradation and finally leading to a 
decrease in the expression of PGC-1 . 
 “Reprinted from Palomer et al., International Journal of Cardiology, 168:3160-3172, 
Copyright  (2013), with permission from Elsevier Limited”. 
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